INTRODUCTION
Clinical practice guidelines (CPGs) are systematically developed statements to assist clinicians and healthcare professionals to make appropriate clinical decisions in specific circumstances. Previous guidelines, which were mainly based on informal expert consensus, were influenced by expert clinical experience, training and subjective judgement. 1 2 With the development of evidencebased medicine (EBM), guidelines increasingly demand the use of evidence, applying the principles of EBM to the process of guideline development. The generation of guideline recommendations involves both content and methodology experts, and the process should be clearly defined and reproducible. 3 The commonly used standard that underpins the development of evidencebased CPGs was initially developed by the Scottish Intercollegiate Guidelines Network (SIGN). 4 Over the past decade clinical guidelines have increasingly become a familiar part of clinical practice, 5 and over the last 5 years the rate of publication of new CPGs has increased rapidly in China. 6 The China Guideline Clearinghouse (CGC) is the major resource for CPGs in China. 7 It is jointly initiated and run by the Evidence-Based Medicine Specialty Committee under the Chinese Medical Doctors' Association and the Chinese
Strengths and limitations of this study
▪ This is the first comprehensive analysis of traditional Chinese medicine (TCM) therapies included in Western medicine clinical practice guidelines in China. ▪ The implications for future updating and development of Western medicine clinical practice guidelines involving TCM are highlighted. ▪ There are limitations to this study as guidelines from other countries that recognise TCM were not included and a rigorous quality assessment of all Chinese clinical practice guidelines was not conducted.
Medical Association journal board. CGC is an internet collection of CPGs published in Chinese medical journals and is used as a platform for clinicians and the public.
Complementary and alternative medicine (CAM) consists of a wide range of healthcare practices, products and therapies. 8 9 Traditional Chinese medicine (TCM) is usually considered to be part of CAM in the West and involves a broad range of medicine practices sharing common concepts that have been developed in China. TCM is based on a tradition that has evolved over more than 3000 years and includes various forms of herbal medicine, acupuncture, massage (Tuina), exercise (Qigong) and dietary therapy. 10 Western medicine and TCM are parallel and equally important healthcare systems in China, and the Chinese government has encouraged the integration of Western medicine and TCM. Currently, the use of Chinese patent herbal medicine is widespread and reimbursed by the government insurance system. Reports have suggested that 60% of Chinese patent herbal medicines are prescribed by medical doctors in Western medicine hospitals.
11 A large-scale survey organised by Beijing Municipal Administration of Traditional Chinese Medicine and Beijing Association of Chinese Medicine found that 40% of prescriptions of patent herbal medicine by Western medicine doctors was inappropriate due to lack of TCM knowledge.
11
This study aims to assess the status of TCM recommended as an intervention in Western medicine CPGs in China and the use of evidence that underpins these recommendations. Our purpose in doing this is to provide an appropriate evidence-based strategy for the development of Western medicine CPGs that include TCM.
METHODS

Inclusion criteria
Guidelines approved and issued by the Ministry of Health of China, the Chinese Medical Association and the Chinese Medical Doctors' Association were all included in the initial review. Subsequently, all CPGs containing TCM were included in the study. Older versions of the guidelines with existing updates were excluded. Subsequent analysis of the 604 CPGs according to the International Classification of Diseases, 10th edition (ICD-10) identified 21 disease systems. Of the 74 guidelines with TCM content, 58 different diseases were identified and these involved 13 specific disease systems (figure 2). In the 74 CPGs with TCM content, one mentioned TCM in the introduction (1%), one in the diagnosis of syndrome differentiation (1%), but most of the guidelines mentioned TCM in the treatment recommendation section (73, 99%). In addition, TCM recommendations were described under prevention (three guidelines, occupying 4% of the total guideline number) and two under rehabilitation (3%). Five guidelines mentioned TCM in more than one section of the guideline.
Data sources
Among the 74 CPGs with TCM content, 43 guidelines (58%) recommended a Chinese herbal treatment (including single herbs or multiple herbs based on syndrome differentiation) and, among them, 25 guidelines (34%) recommended Chinese proprietary medicine or herbal preparations produced by a hospital pharmacy and not necessarily approved by the State Food and Drug Administration. In addition, 14 guidelines (19%) recommended acupuncture, one guideline recommended acupuncture point injection (1%) and 14 guidelines recommended two or more TCM therapies (table 2) .
Of the 74 CPGs with TCM content, only five guidelines (7%) provided evidence grading for the TCM recommendations. 50 51 53 54 56 Three guidelines reported level I evidence related to TCM, 50 53 54 four guidelines reported level II evidence related to acupuncture and herbal extracts 41 53 54 58 and three guidelines reported level III evidence related to Chinese patent medicine and massage. 53 54 64 All these guidelines specified the herbal compositions (table 3) .
Two of the 74 CPGs with TCM content mentioned that "due to the limited literature involving TCM studies and small sample sizes, more evidence was needed before making firm recommendations" and "further high-quality studies should be conducted to confirm the effects of TCM treatments". 51 53 Three guidelines did not provide further comments after recommending TCM treatments. 50 52 58 The other 69 guidelines did not provide the evidence level for their recommendation for TCM treatments, but only listed a general statementfor example, "TCM treatment: apply TCM treatment methods such as herbal medicines, acupuncture, acupoint injection, and Tuina, which should be based on syndrome differentiation". 20 Of the 74 CPGs with TCM content, only 11 mentioned appropriate references to TCM such as systematic reviews (n=3), 51 53 71 randomised controlled trials (n=6), 17 50 51 54 58 71 non-randomised controlled trials (n=2), 54 58 case series (n=4) 24 51 54 71 or other (n=1) (historical TCM classical texts). 82 
DISCUSSION
Few Western medicine CPGs in China recommended TCM, and very few guidelines applied an evidence-based approach in the recommendations. The majority of the TCM therapies (58%) recommended were Chinese herbal medicine, and about 59% of the recommendations were for chronic diseases such as chronic hepatitis B, bronchial asthma and type 2 diabetes mellitus. The TCM content of the 74 CPGs failed to provide adequate references to research published in international journals. In addition, the methodology regarding how the TCM recommendations were formulated was not transparent or evidence-based.
This study systematically assessed the status of TCM therapy recommended in 604 Western medicine CPGs issued by three state level organisations in China. To the best of our knowledge, this is the first comprehensive analysis detailing the inclusion of TCM content in Western medicine CPGs published in China. Recommendations for TCM in the current Chinese guidelines are not reflected by its popularity in practice. The findings of this study provide insights for the future development and updating of CPGs involving Western medicine and TCM in China.
This study has some limitations. First, the included guidelines were all identified from the China Guideline Clearinghouse and issued by the Ministry of Health, the Chinese Medical Association and the Chinese Medical Doctors' Association. These guidelines are easily accessible and published centrally but may not be comprehensive as some guidelines may be issued by other relevant Chinese professional societies. Second, we did not include guidelines from other countries that recognise TCM (eg, the use of acupuncture for pain in the USA and Europe) so we are unable to comment about the specific evidence for TCM in treatment guidelines in other countries. Third, we only evaluated evidence grading in those CPGs that recommended TCM so we are not able to reach any conclusions about the CPGs that did not recommend TCM.
This study shows that Western medicine CPGs do not include adequate relevant research to support the guidelines' recommendations for TCM. It appears that trials and systematic reviews carried out in the West may not be included as evidence even though the research may be of good quality. One article published in 2014 identified 13 guidelines and 22 systematic reviews issued by East Asian countries on traditional medicine (including acupuncture, moxibustion, cupping, herbal medicine, TCM, manual therapy and Tuina) for low back pain. 87 This study suggested that the current CPGs do not fully reflect the evidence for traditional medicine interventions and concluded that, as relevant studies, systematic reviews and meta-analyses are conducted and the evidence increases, the current evidence on acupuncture, herbal medicine and manual therapy should be reconsidered in the process of developing or updating relevant CPGs. Similarly, in the UK, a recent study of NHS Western medical clinical guidelines issued by the National Institute for Health and Care Excellence demonstrated a low proportion of CPGs mentioning at least one CAM. 88 Out of 279 UK clinical guidelines issued during 2006-2013, only 16% mentioned CAM, with acupuncture and natural herbal medicines being the most common. For acupuncture, six guidelines recommended its use, three stated that it could be considered but the evidence was weak, 18 could not recommend acupuncture based on the available evidence and six advised against the use of acupuncture. Thirty-six guidelines mentioned the use of various natural products including herbs. Interestingly, there were more guidelines mentioning acupuncture in the UK than there were in China over the same time period. 88 Our study shows that there is insufficient application of TCM research evidence in Western medicine guidelines in China. This may be because the guideline developers did not identify the relevant evidence when preparing the guidelines, but it is important to note that most of the guidelines did not have clear methodology for how they had been developed. One recent study reported that there were 2964 controlled clinical trials involving TCM in cancer treatment published in China between1984 and 2011, and the number of such publications increases annually, but these data do not seem to have been used in guideline development. 89 CAM including TCM mainly due to the poor methodological quality of the original studies. 92 Thus, whether there is adequate evidence to recommend TCM in guidelines included in this study is still not known, and this should be the focus of future research.
In spite of these caveats, it appears that (1) there is insufficient evidence to recommend TCM for some conditions and further research is required; (2) the evidence on the quality, safety and efficacy of traditional medicine does not meet the applicable standards for Western medicine; 93 and (3) Chinese guidelines are generally of poor quality and have mostly been developed through expert consensus and lack rigorous scientific methodology. 94 Based on the findings from our study, we make the following suggestions for the future development of Chinese clinical guidelines. First, all guidelines should be evidence-based so that the recommendations can be supported by research evidence. Adopting an evidencebased approach to the development of CPGs has become an international trend, 4 and CPGs should be founded on the highest quality of scientific evidence available. In the Chinese context (reflecting the popularity of TCM), considerable effort should be made to look at both Western medicine and TCM to reflect and support their clinical use. Second, many of the original Chinese studies are of poor quality, challenging their utility as evidence in China and abroad, 95 and there is an urgent need to improve the methodology and reporting of randomised controlled trials in China. Third, different stakeholders should be involved in the development of CPGs such as Western medical doctors, TCM practitioners, methodologists, information personnel, nurses and healthcare policy makers. 96 CONCLUSIONS TCM is included in 12% of Western medicine guidelines in China. Few guidelines that recommend TCM provide references, and very few have applied evidence grading to support their recommendations. Future guideline development in China should be based on internationally recognised methodology with relevant stakeholders involved. We suggest systematic searching and synthesising of evidence, critical appraisal of evidence, and reporting the evidence with reference to the Grading of Quality evidence based on GRADE: A, high quality; B, moderate quality; C, low quality; D, very low quality. Quality level based on GRADE: 1. High: we are very confident that the true effect lies close to that of the estimate of the effect. 2. Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect but there is a possibility that it is substantially different. 3. Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. 4. Very low: we have very little confidence in the effect estimate; the effect is likely to be substantially different from the estimate of effect. *Although the two articles have partially similar content, we regarded them as different guidelines because of different form and part of the content. †If level of evidence involved did not identify a specific standard, it was assessed based on GRADE standards. 86 AD, Alzheimer's disease; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; MCI, mild cognitive impairment.
Recommendations, Assessment, Development and Evaluation (GRADE) 97 using the Appraisal of Guidelines for Research and Evaluation (AGREE) format (http:// www.agreecollaboration.org).
